Daiichi Sankyo officials to monitor new Ranbaxy unit
Daiichi Sankyo, the Japanese owner of Ranbaxy Laboratories, has deputed two executives to monitor the Indian drug maker’s new plant that will be the main source for supplying medicines for the US market. A person aware of the development said these two executives, who are at the general manager and director level, would be based […]
Read More »Category : News
Roche Refuses To Disclose Tamiflu Data: Scientists
An influential review that is due out tomorrow will not contain up-to-date efficacy information about Tamiflu, the widely used influenza drug sold by Roche, because researchers at the Cochrane Collaboration say they were stymied by the drugmaker in their efforts to fully assess the medication, according to reports. Iain Chalmers, one of the founders of […]
Read More »Category : News
J&J Marketed Risperdal for Kids After FDA Warnings, Jurors Told
The antipsychotic drug Risperdal was marketed for children and adolescents by Johnson & Johnson’s Janssen unit after warnings by the U.S. Food and Drug Administration not to do so, a witness told jurors. Janssen’s marketing to children began after the drug’s introduction in 1994 and continued until the FDA’s first approval for pediatric uses in […]
Read More »Category : News
American Red Cross Cited by FDA for Blood-Safety Rule Violations
The American Red Cross, the biggest U.S. supplier of donated blood, failed to correct violations of blood-safety rules, raising the risk that ill-suited blood will be used in transfusions, U.S. regulators said. The U.S. Food and Drug Administration fined the Red Cross $9.59 million, according to a letter from the agency to the Red Cross […]
Read More »Category : News
FDA Warns of Counterfeit Cancer Drugs
Shortages of some injectable cancer drugs have created an opening for dangerous unapproved versions of Roche Holding AG’s Herceptin and Amgen’s Neupogen to be sold to clinics and other healthcare providers, U.S. health officials said. The Food and Drug Administration issued a notice Friday warning providers to avoid direct solicitations from unproven sources and only […]
Read More »Category : News
FDA would collect millions in fees to speed review of traditional and biotech generic drugs
The Food and Drug Administration would collect hundreds of millions of dollars in new fees from pharmaceutical companies to help speed up the review of generic drugs, under an agreement with industry released by the agency on Friday. The user fee proposal is one of three such agreements that the agency is submitting to Congress […]
Read More »Category : News
FDA warns about PML risk with Seattle Genetics’ Adcetris
Seattle Genetics has suffered a setback on the news that US regulators have called for a boxed warning on the lymphoma drug Adcetris amid concerns of a link to a rare but potentially fatal brain infection. The US Food and Drug Administration said the warning needs to be added to the label after two additional […]
Read More »Category : News
Novartis Cuts Another 2,000 Jobs In The US
Just one more after a key clinical trial for its Tekturna hypertension pill was a bust – there was evidence of an increased incidence of non-fatal stroke, renal complications, hyperkalemia and hypotension – Novartis has decided to eliminate 1,960 jobs in the US, including 1,630 sales reps and another 330 positions at its US headquarters […]
Read More »Category : News
Walgreen Accused in Suit of Plotting With Par to Overcharge for Generics
Walgreen Co., the biggest U.S. drugstore chain, and generic drugmaker Par Pharmaceutical Cos. (PRX) swapped prescription-drug tablets for more expensive capsules to boost profits, a union benefits fund claimed in a lawsuit. “Walgreen’s and Par engaged in at least two widespread schemes to overcharge insurance companies, self-insured employers and union health and welfare funds,†the […]
Read More »Category : News
Resveratrol Researcher Falsified 145 Studies
If you were skeptical about the links between a substance found in red wine and developing a fountain-of-youth pill, you have still more reason today. A University of Connecticut researcher named Dipak Das, who studied those supposed links and directed the school’s cardiovascular research center, fabricated or falsified research data as many as 145 times. […]
Read More »Category : News
